Literature DB >> 19102685

Short communication: In vitro synergy between peptides or neutralizing antibodies targeting the N- and C-terminal heptad repeats of HIV Type 1 gp41.

Renee Hrin1, Donna L Montgomery, Fubao Wang, Jon H Condra, Zhiqiang An, William R Strohl, Elisabetta Bianchi, Antonello Pessi, Joseph G Joyce, Ying-Jie Wang.   

Abstract

Class 1 and class 2 fusion peptides bind to the trimeric N-terminal heptad repeat (NHR) and C-terminal heptad repeat (CHR) regions of HIV-1 envelope glycoprotein gp41, respectively, and block its intramolecular folding required for Env-mediated viral and host cell membrane fusion and subsequent viral entry. Using a combination of T-20 (class 1) and (CCIZN17)(3) (class 2), we provide evidence that these classes of fusion peptides work synergistically in an in vitro infectivity assay in inhibiting the entry of primary HIV-1 isolate 89.6 with combination indexes reaching 0.37 and 0.32 at IC(50) and IC(90), respectively. We further demonstrate a similar degree of neutralization synergy between a monoclonal antibody (MAb), D5, targeting the hydrophobic pocket region of the NHR, and 2F5, a well-characterized MAb that targets the C-terminal end of CHR and the membrane-proximal external region (MPER), providing a rational basis for developing combination vaccines targeting these two highly conserved regions of gp41.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19102685     DOI: 10.1089/aid.2008.0129

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  9 in total

1.  Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors.

Authors:  Thomas J Ketas; Sophie Holuigue; Katie Matthews; John P Moore; Per Johan Klasse
Journal:  Virology       Date:  2011-10-22       Impact factor: 3.616

2.  Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41.

Authors:  Donna L Montgomery; Ying-Jie Wang; Renee Hrin; Micah Luftig; Bin Su; Michael D Miller; Fubao Wang; Peter Haytko; Lingyi Huang; Salvatore Vitelli; Jon Condra; Xiaomei Liu; Richard Hampton; Andrea Carfi; Antonello Pessi; Elisabetta Bianchi; Joseph Joyce; Chris Lloyd; Romas Geleziunas; David Bramhill; Vicki M King; Adam C Finnefrock; William Strohl; Zhiqiang An
Journal:  MAbs       Date:  2009-09-08       Impact factor: 5.857

3.  HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities.

Authors:  Justin Pollara; Mattia Bonsignori; M Anthony Moody; Pinghuang Liu; S Munir Alam; Kwan-Ki Hwang; Thaddeus C Gurley; Daniel M Kozink; Lawrence C Armand; Dawn J Marshall; John F Whitesides; Jaranit Kaewkungwal; Sorachai Nitayaphan; Punnee Pitisuttithum; Supachai Rerks-Ngarm; Merlin L Robb; Robert J O'Connell; Jerome H Kim; Nelson L Michael; David C Montefiori; Georgia D Tomaras; Hua-Xin Liao; Barton F Haynes; Guido Ferrari
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

Review 4.  Peptides in the treatment of AIDS.

Authors:  Fred Naider; Jacob Anglister
Journal:  Curr Opin Struct Biol       Date:  2009-07-23       Impact factor: 6.809

5.  Novel neutralising antibodies targeting the N-terminal helical region of the transmembrane envelope protein p15E of the porcine endogenous retrovirus (PERV).

Authors:  Alexander Waechter; Joachim Denner
Journal:  Immunol Res       Date:  2014-01       Impact factor: 2.829

6.  Structural basis of HIV-1 neutralization by affinity matured Fabs directed against the internal trimeric coiled-coil of gp41.

Authors:  Elena Gustchina; Mi Li; John M Louis; D Eric Anderson; John Lloyd; Christian Frisch; Carole A Bewley; Alla Gustchina; Alexander Wlodawer; G Marius Clore
Journal:  PLoS Pathog       Date:  2010-11-11       Impact factor: 6.823

7.  Crystal structure and size-dependent neutralization properties of HK20, a human monoclonal antibody binding to the highly conserved heptad repeat 1 of gp41.

Authors:  Charles Sabin; Davide Corti; Victor Buzon; Mike S Seaman; David Lutje Hulsik; Andreas Hinz; Fabrizia Vanzetta; Gloria Agatic; Chiara Silacci; Lara Mainetti; Gabriella Scarlatti; Federica Sallusto; Robin Weiss; Antonio Lanzavecchia; Winfried Weissenhorn
Journal:  PLoS Pathog       Date:  2010-11-18       Impact factor: 6.823

8.  Selected amino acid mutations in HIV-1 B subtype gp41 are associated with specific gp120v₃ signatures in the regulation of co-receptor usage.

Authors:  Salvatore Dimonte; Fabio Mercurio; Valentina Svicher; Roberta D'Arrigo; Carlo-Federico Perno; Francesca Ceccherini-Silberstein
Journal:  Retrovirology       Date:  2011-05-12       Impact factor: 4.602

9.  Dramatic potentiation of the antiviral activity of HIV antibodies by cholesterol conjugation.

Authors:  Krzysztof Lacek; Richard A Urbanowicz; Fulvia Troise; Claudia De Lorenzo; Valeria Severino; Antimo Di Maro; Alexander W Tarr; Francesca Ferrara; Alexander Ploss; Nigel Temperton; Jonathan K Ball; Alfredo Nicosia; Riccardo Cortese; Antonello Pessi
Journal:  J Biol Chem       Date:  2014-10-23       Impact factor: 5.157

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.